Press "Enter" to skip to content

What we’re reading: Not all approve with FDA’s Alzheimer treatment drug approval

Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug

Pam Belluck and Rebecca Robbins – New York Times

In a powerful statement of disagreement with the Food and Drug Administration’s approval of Biogen’s controversial Alzheimer’s drug, three scientists have resigned from the independent committee that advised the agency on the treatment. … expressing dismay at the approval of the drug despite the committee’s overwhelming rejection of it after reviewing clinical trial data in November.

None of the 11 members of the committee considered the drug ready for approval: Ten voted against and one was uncertain.

Advertisement

Click for more information
Advertisement

Click for more information

My custom footer text